KMT2A and leukemia: KMT2A exerts its function by forming a core-complex with other proteins [66]; for this reason, the inhibition of KMT2A with its interaction partners, both histone and non-histone proteins, is a promising pharmacological strategy when KMT2A rearrangements are drivers of pathology, such as in leukemia.